loading...| Preferred Name | Lopinavir/Ritonavir | |
| Synonyms |
Lopinavir/Ritonavir lopinavir/ritonavir Kaletra |
|
| Definitions |
A fixed combination of two protease inhibitors, lopinavir and ritonavir, used to treat human immunodeficiency virus (HIV) infection. The ritonavir in the combination drug increases the concentration and biological half-life of lopinavir but is not present in sufficient concentration to act as a protease inhibitor. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C2096 |
|
| ALT_DEFINITION |
A combination of the drugs ritonavir and lopinavir. It is used to treat infection with HIV (the virus that causes AIDS). It is also being studied in the treatment of some types of cancer. Lopinavir/ritonavir blocks the ability of HIV to make copies of itself and may help other anticancer drugs work better or may block the growth of cancer cells. Ritonavir blocks the breakdown of lopinavir. Lopinavir/ritonavir is a type of anti-HIV agent and a type of protease inhibitor. |
|
| alternative_term |
Lopinavir/Ritonavir lopinavir/ritonavir Kaletra |
|
| code |
C2096 |
|
| definition |
A fixed combination of two protease inhibitors, lopinavir and ritonavir, used to treat human immunodeficiency virus (HIV) infection. The ritonavir in the combination drug increases the concentration and biological half-life of lopinavir but is not present in sufficient concentration to act as a protease inhibitor. |
|
| fromArticle |
true |
|
| imported from | ||
| label |
Lopinavir/Ritonavir |
|
| Legacy_Concept_Name |
Lopinavir_Ritonavir |
|
| oboInOwl:hasExactSynonym |
Lopinavir + ritonavir |
|
| preferred label |
Lopinavir/Ritonavir |
|
| Preferred_Name |
Lopinavir/Ritonavir |
|
| prefixIRI |
NCIT:C2096 |
|
| prefLabel |
Lopinavir/Ritonavir |
|
| see also |
https://www.cebm.net/covid-19/registered-trials-and-analysis/ |
|
| Semantic_Type |
Pharmacologic Substance |
|
| textual definition |
A fixed combination of two protease inhibitors, lopinavir and ritonavir, used to treat human immunodeficiency virus (HIV) infection. The ritonavir in the combination drug increases the concentration and biological half-life of lopinavir but is not present in sufficient concentration to act as a protease inhibitor. |
|
| UMLS_CUI |
C0939237 |
|
| subClassOf |